发明名称 |
Immunoconjugates |
摘要 |
The present invention relates to new fusion proteins which consist of a tumor-associated targeting element preferentially a monoclonal antibody or a fragment thereof recognizing a molecule which is preferentially expressed on human tumor cells such as the human epidermal growth factor receptor (EGFR), and a biologically active ligand such as a growth and/or differentiation factor. The resulting fusion protein may be used to deliver the biologically active ligand to a specific target cell or tissue. The new immunoconjugates can be used in tumor therapy. |
申请公布号 |
AU688817(B2) |
申请公布日期 |
1998.03.19 |
申请号 |
AU19940081593 |
申请日期 |
1994.12.20 |
申请人 |
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG |
发明人 |
DR. CARLOTA-SILVIA JAGGLE;N UWE HOFMANN;N ILKA VON HOEGEN;DR. WOLFGANG STRITTMATTER;DR SIEGFRIED MATZKU |
分类号 |
C12N15/09;A61K;A61K38/00;A61K38/16;A61K38/18;A61K38/19;A61K38/20;A61K39/00;A61K39/295;A61K39/395;A61K39/44;A61K47/48;A61P35/00;A61P35/04;C07K;C07K14/52;C07K14/525;C07K14/54;C07K14/55;C07K16/00;C07K16/28;C07K16/30;C07K16/42;C07K16/46;C07K19/00;C12N;C12N15/13;C12N15/19;C12N15/55;C12N15/62;C12N15/64;C12N15/72;C12N15/79;C12P21/02;C12P21/08;C12R1/19;C12R1/91;(IPC1-7):C12N15/62 |
主分类号 |
C12N15/09 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|